Seek Returns logo

ABBV vs. RGC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ABBV’s market capitalization of 334.34 billion USD is substantially larger than RGC’s 11.37 billion USD, indicating a significant difference in their market valuations.

RGC carries a higher beta at 2.62, indicating it’s more sensitive to market moves, while ABBV (beta: 0.49) exhibits greater stability.

SymbolABBVRGC
Company NameAbbVie Inc.Regencell Bioscience Holdings Limited
CountryUSHK
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralDrug Manufacturers - Specialty & Generic
CEORobert A. Michael CPAYat-Gai Au
Price189.28 USD22.99 USD
Market Cap334.34 billion USD11.37 billion USD
Beta0.492.62
ExchangeNYSENASDAQ
IPO DateJanuary 2, 2013July 16, 2021
ADRNoNo

Historical Performance

This chart compares the performance of ABBV and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ABBV vs. RGC: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ABBV

95.59%

Drug Manufacturers - General Industry

Max
95.59%
Q3
76.92%
Median
30.71%
Q1
8.97%
Min
-14.85%

In the upper quartile for the Drug Manufacturers - General industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RGC

-25.23%

Drug Manufacturers - Specialty & Generic Industry

Max
51.32%
Q3
9.89%
Median
-3.37%
Q1
-20.99%
Min
-36.07%

RGC has a negative Return on Equity of -25.23%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ABBV vs. RGC: A comparison of their ROE against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Return on Invested Capital

ABBV

17.93%

Drug Manufacturers - General Industry

Max
25.72%
Q3
17.89%
Median
11.47%
Q1
9.39%
Min
2.87%

In the upper quartile for the Drug Manufacturers - General industry, ABBV’s Return on Invested Capital of 17.93% signifies a highly effective use of its capital to generate profits when compared to its peers.

RGC

-28.41%

Drug Manufacturers - Specialty & Generic Industry

Max
22.54%
Q3
8.45%
Median
1.42%
Q1
-9.01%
Min
-28.41%

RGC has a negative Return on Invested Capital of -28.41%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ABBV vs. RGC: A comparison of their ROIC against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Net Profit Margin

ABBV

7.31%

Drug Manufacturers - General Industry

Max
34.51%
Q3
23.04%
Median
14.73%
Q1
11.78%
Min
2.18%

Falling into the lower quartile for the Drug Manufacturers - General industry, ABBV’s Net Profit Margin of 7.31% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

RGC

--

Drug Manufacturers - Specialty & Generic Industry

Max
40.33%
Q3
11.92%
Median
-0.45%
Q1
-13.07%
Min
-34.27%

Net Profit Margin data for RGC is currently unavailable.

ABBV vs. RGC: A comparison of their Net Profit Margin against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Operating Profit Margin

ABBV

28.31%

Drug Manufacturers - General Industry

Max
40.70%
Q3
28.90%
Median
23.41%
Q1
19.05%
Min
16.13%

ABBV’s Operating Profit Margin of 28.31% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.

RGC

--

Drug Manufacturers - Specialty & Generic Industry

Max
46.91%
Q3
19.02%
Median
6.23%
Q1
-11.23%
Min
-51.89%

Operating Profit Margin data for RGC is currently unavailable.

ABBV vs. RGC: A comparison of their Operating Margin against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Profitability at a Glance

SymbolABBVRGC
Return on Equity (TTM)95.59%-25.23%
Return on Assets (TTM)3.08%-26.51%
Return on Invested Capital (TTM)17.93%-28.41%
Net Profit Margin (TTM)7.31%--
Operating Profit Margin (TTM)28.31%--
Gross Profit Margin (TTM)77.46%--

Financial Strength

Current Ratio

ABBV

0.76

Drug Manufacturers - General Industry

Max
1.67
Q3
1.37
Median
1.26
Q1
0.87
Min
0.39

ABBV’s Current Ratio of 0.76 falls into the lower quartile for the Drug Manufacturers - General industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RGC

41.92

Drug Manufacturers - Specialty & Generic Industry

Max
5.74
Q3
3.37
Median
2.64
Q1
1.73
Min
0.88

RGC’s Current Ratio of 41.92 is exceptionally high, placing it well outside the typical range for the Drug Manufacturers - Specialty & Generic industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

ABBV vs. RGC: A comparison of their Current Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Debt-to-Equity Ratio

ABBV

49.22

Drug Manufacturers - General Industry

Max
2.95
Q3
2.44
Median
0.86
Q1
0.68
Min
0.09

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Drug Manufacturers - General industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

RGC

0.01

Drug Manufacturers - Specialty & Generic Industry

Max
1.45
Q3
1.06
Median
0.62
Q1
0.13
Min
0.00

Falling into the lower quartile for the Drug Manufacturers - Specialty & Generic industry, RGC’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

ABBV vs. RGC: A comparison of their D/E Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Interest Coverage Ratio

ABBV

6.14

Drug Manufacturers - General Industry

Max
27.46
Q3
14.40
Median
7.80
Q1
4.07
Min
1.67

ABBV’s Interest Coverage Ratio of 6.14 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.

RGC

--

Drug Manufacturers - Specialty & Generic Industry

Max
10.17
Q3
3.39
Median
0.85
Q1
-2.63
Min
-5.84

Interest Coverage Ratio data for RGC is currently unavailable.

ABBV vs. RGC: A comparison of their Interest Coverage against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Financial Strength at a Glance

SymbolABBVRGC
Current Ratio (TTM)0.7641.92
Quick Ratio (TTM)0.6441.92
Debt-to-Equity Ratio (TTM)49.220.01
Debt-to-Asset Ratio (TTM)0.510.01
Net Debt-to-EBITDA Ratio (TTM)3.960.66
Interest Coverage Ratio (TTM)6.14--

Growth

The following charts compare key year-over-year (YoY) growth metrics for ABBV and RGC. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ABBV vs. RGC: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ABBV vs. RGC: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ABBV vs. RGC: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ABBV

3.37%

Drug Manufacturers - General Industry

Max
8.72%
Q3
4.10%
Median
3.34%
Q1
1.89%
Min
0.00%

ABBV’s Dividend Yield of 3.37% is consistent with its peers in the Drug Manufacturers - General industry, providing a dividend return that is standard for its sector.

RGC

0.00%

Drug Manufacturers - Specialty & Generic Industry

Max
9.29%
Q3
0.31%
Median
0.00%
Q1
0.00%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ABBV vs. RGC: A comparison of their Dividend Yield against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Dividend Payout Ratio

ABBV

266.46%

Drug Manufacturers - General Industry

Max
266.46%
Q3
78.91%
Median
60.27%
Q1
43.74%
Min
0.00%

ABBV’s Dividend Payout Ratio of 266.46% is above 100%. This means the company is paying out more in dividends than it earned, a practice that is often unsustainable and could indicate a risk to future dividend stability.

RGC

0.00%

Drug Manufacturers - Specialty & Generic Industry

Max
125.42%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ABBV vs. RGC: A comparison of their Payout Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Dividend at a Glance

SymbolABBVRGC
Dividend Yield (TTM)3.37%0.00%
Dividend Payout Ratio (TTM)266.46%0.00%

Valuation

Price-to-Earnings Ratio

ABBV

79.77

Drug Manufacturers - General Industry

Max
27.96
Q3
25.84
Median
18.32
Q1
16.65
Min
3.39

At 79.77, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - General industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

RGC

-5,081.11

Drug Manufacturers - Specialty & Generic Industry

Max
40.89
Q3
28.12
Median
23.94
Q1
18.79
Min
7.76

RGC has a negative P/E Ratio of -5,081.11. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ABBV vs. RGC: A comparison of their P/E Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Forward P/E to Growth Ratio

ABBV

7.21

Drug Manufacturers - General Industry

Max
3.10
Q3
3.09
Median
2.72
Q1
2.18
Min
1.02

ABBV’s Forward PEG Ratio of 7.21 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.

RGC

-336.62

Drug Manufacturers - Specialty & Generic Industry

Max
4.19
Q3
2.94
Median
1.47
Q1
0.35
Min
0.00

RGC has a negative Forward PEG Ratio of -336.62. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

ABBV vs. RGC: A comparison of their Forward PEG Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Price-to-Sales Ratio

ABBV

5.83

Drug Manufacturers - General Industry

Max
6.47
Q3
4.47
Median
3.53
Q1
1.96
Min
0.41

ABBV’s P/S Ratio of 5.83 is in the upper echelon for the Drug Manufacturers - General industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RGC

--

Drug Manufacturers - Specialty & Generic Industry

Max
7.49
Q3
4.45
Median
2.12
Q1
1.21
Min
0.25

P/S Ratio data for RGC is currently unavailable.

ABBV vs. RGC: A comparison of their P/S Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Price-to-Book Ratio

ABBV

235.67

Drug Manufacturers - General Industry

Max
7.80
Q3
7.80
Median
5.30
Q1
4.06
Min
1.08

The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.

RGC

1,383.22

Drug Manufacturers - Specialty & Generic Industry

Max
4.93
Q3
3.95
Median
2.14
Q1
1.30
Min
0.13

The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.

ABBV vs. RGC: A comparison of their P/B Ratio against their respective Drug Manufacturers - General and Drug Manufacturers - Specialty & Generic industry benchmarks.

Valuation at a Glance

SymbolABBVRGC
Price-to-Earnings Ratio (P/E, TTM)79.77-5081.11
Forward PEG Ratio (TTM)7.21-336.62
Price-to-Sales Ratio (P/S, TTM)5.83--
Price-to-Book Ratio (P/B, TTM)235.671383.22
Price-to-Free Cash Flow Ratio (P/FCF, TTM)21.73--
EV-to-EBITDA (TTM)24.39-2604.14
EV-to-Sales (TTM)6.96--